Pharmacogenetic Testing-Guided Treatment for Oncology: An Overview of Reviews

References

• Chang W-C , TanoshimaR , RossCJD , CarletonBC. Challenges and opportunities in implementing pharmacogenetic testing in clinical settings. Annu. Rev. Pharmacol. Toxicol.61, 65–84 (2021).
   PubMed Web of Science ®Google Scholar
• Keks N , HopeJ , KeoghS. Switching and stopping antidepressants. Aust. Prescr.39(3), 76–83 (2016).
   PubMedGoogle Scholar
• Faruque F , NohH , HussainA , NeubergerE , OnukwughaE. Economic value of pharmacogenetic testing for cancer drugs with clinically relevant drug–gene associations: a systematic literature review. J. Manag. Care Spec. Pharm.25(2), 260–271 (2019).
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M , HuddartR , GongLet al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther.110(3), 563–572 (2021).
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M , McDonaghEM , HebertJMet al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther.92(4), 414–417 (2012).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , CaseyST , Whirl-CarrilloM , MillerNA , KleinTE. Pharmacogene variation consortium: a global resource and repository for pharmacogene variation. Clin. Pharmacol. Ther.110(3), 542–545 (2021).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , Whirl-CarrilloM , PrattVM , MillerNA , KleinTE. PharmVar and the landscape of pharmacogenetic resources. Clin. Pharmacol. Ther.107(1), 43–46 (2020).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , Ingelman-SundbergM , MillerNAet al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin. Pharmacol. Ther.103(3), 399–401 (2018).
   PubMed Web of Science ®Google Scholar
• Relling MV , KleinTE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther.89(3), 464–467 (2011).
   PubMed Web of Science ®Google Scholar
• Home: ClinicalTrials.gov. www.clinicaltrials.gov/
   Google Scholar
• US Food and Drug Administration . Table of pharmacogenomic biomarkers in drug labeling (2021). www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
   Google Scholar
• Berm EJJ , de LooffM , WilffertBet al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. second update of the literature. PLOS ONE11(1), e0146262 (2016).
   PubMed Web of Science ®Google Scholar
• Johnson JA , BurkleyBM , LangaeeTY , Clare-SalzlerMJ , KleinTE , AltmanRB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther.92(4), 437–439 (2012).
   PubMed Web of Science ®Google Scholar
• Borobia AM , DapiaI , TongHYet al. Clinical implementation of pharmacogenetic testing in a hospital of the Spanish national health system: strategy and experience over 3 years. Clin. Transl. Sci.11(2), 189–199 (2018).
   PubMed Web of Science ®Google Scholar
• Haga SB . Pharmacogenomic testing in pediatrics: navigating the ethical, social, and legal challenges. Pharmgenomics Pers. Med.12, 273–285 (2019).
   PubMed Web of Science ®Google Scholar
• PROSPERO (2020). www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=198206
   Google Scholar
• Page MJ , McKenzieJE , BossuytPMet al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ372, n71 (2021).
   PubMed Web of Science ®Google Scholar
• Zhu Y , SwansonKM , RojasRLet al. Systematic review of the evidence on the cost–effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet. Med.22(3), 475–486 (2020).
   PubMed Web of Science ®Google Scholar
• Ouzzani M , HammadyH , FedorowiczZ , ElmagarmidA. Rayyan – a web and mobile app for systematic reviews. Syst. Rev.5(1), 210 (2016).
   PubMedGoogle Scholar
• Shea BJ , ReevesBC , WellsGet al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ358, j4008 (2017).
   PubMed Web of Science ®Google Scholar
• Aromataris E , FernandezR , GodfreyCM , HollyC , KhalilH , TungpunkomP. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int. J. Evid. Based Healthc.13(3), 132–140 (2015).
   PubMed Web of Science ®Google Scholar
• Pollock M , FernandesRM , BeckerLAet al. Chapter V: overviews of reviews. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.2.Cochrane (2021). www.training.cochrane.org/handbook
   Google Scholar
• Ahern TP , HertzDL , DamkierPet al. Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: evaluating the importance of loss of heterozygosity. Am. J. Epidemiol.185(2), 75–85 (2017).
   PubMed Web of Science ®Google Scholar
• Drögemöller BI , WrightGEB , ShihJet al. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res. Treat.173(3), 521–532 (2019).
   PubMed Web of Science ®Google Scholar
• Fleeman N , MartinSaborido C , PayneKet al. The clinical effectiveness and cost–effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol. Assess.15(33), 1–102 (2011).
   Web of Science ®Google Scholar
• Loh M , ChuaD , YaoYet al. Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies? Pharmacogenomics J. 13(5), 423–429 (2013).
   PubMed Web of Science ®Google Scholar
• Lum DWK , PerelP , HingoraniAD , HolmesMV. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLOS ONE8(10), e76648 (2013).
   PubMed Web of Science ®Google Scholar
• Zeng Z , LiuY , LiuZet al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer Chemother. Pharmacol.72(2), 287–303 (2013).
   PubMed Web of Science ®Google Scholar
• Hayden JA , CôtéP , BombardierC. Evaluation of the quality of prognosis studies in systematic reviews. Ann. Intern. Med.144(6), 427–437 (2006).
   PubMed Web of Science ®Google Scholar
• Jorgensen AL , WilliamsonPR. Methodological quality of pharmacogenetic studies: issues of concern. Stat. Med.27(30), 6547–6569 (2008).
   PubMed Web of Science ®Google Scholar
• Goetz MP , KnoxSK , SumanVJet al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101(1), 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Santiago S , ZárateR , Haba-RodríguezJet al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. J. Clin. Oncol.25(Suppl. 18), 590–590 (2007).
   Web of Science ®Google Scholar
• Newman WG , HadfieldKD , LatifAet al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res.14(18), 5913–5918 (2008).
   PubMed Web of Science ®Google Scholar
• Schroth W , AntoniadouL , FritzPet al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol.25(33), 5187–5193 (2007).
   PubMed Web of Science ®Google Scholar
• Schroth W , GoetzMP , HamannUet al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA302(13), 1429–1436 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson AM , QuinlanP , BraySet al. CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Symposium. CA, USA (2009).
   Google Scholar
• Nowell SA , AhnJ , RaeJMet al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat.91(3), 249–258 (2005).
   PubMed Web of Science ®Google Scholar
• Wegman P , ElingaramiS , CarstensenJ , StålO , NordenskjöldB , WingrenS. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res.9(1), R7 (2007).
   PubMed Web of Science ®Google Scholar
• Wegman P , VainikkaL , StålOet al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res.7(3), R284–R290 (2005).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , MushirodaT , ImamuraCKet al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol.28(8), 1287–1293 (2010).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , MushirodaT , SasaMet al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci.99(5), 995–999 (2008).
   PubMed Web of Science ®Google Scholar
• Lim H-S , JuLee H , SeokLee K , SookLee E , JangI-J , RoJ. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol.25(25), 3837–3845 (2007).
   PubMed Web of Science ®Google Scholar
• Okishiro M , TaguchiT , JinKim S , ShimazuK , TamakiY , NoguchiS. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer115(5), 952–961 (2009).
   PubMed Web of Science ®Google Scholar
• Toyama T , YamashitaH , SugiuraH , KondoN , IwaseH , FujiiY. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn. J. Clin. Oncol.39(10), 651–656 (2009).
   PubMed Web of Science ®Google Scholar
• Xu Y , SunY , YaoLet al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol.19(8), 1423–1429 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson MR , WangK , DiasioRB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res.8(3), 768–774 (2002).
   PubMed Web of Science ®Google Scholar
• Jorgensen AL , FitzGeraldRJ , OyeeJ , PirmohamedM , WilliamsonPR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLOS ONE7(8), e44064 (2012).
   PubMed Web of Science ®Google Scholar
• Chan CWH , LiC , XiaoEJet al. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Expert Rev. Mol. Med.24, e1 (2022).
   PubMed Web of Science ®Google Scholar
• Glewis S , AlexanderM , KhabibMNHet al. A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. Br. J. Cancer127(1), 126–136 (2022).
   PubMed Web of Science ®Google Scholar
• Gates M , GatesA , PieperDet al. Reporting guideline for overviews of reviews of healthcare interventions: the Preferred Reporting Items for Overviews of Reviews (PRIOR) statement (2022) ( Epub ahead of print).
   Google Scholar